Get the Stockscreener App
1.12
1.32%
-0.015
Tscan Therapeutics Inc stock is traded at $1.12, with a volume of 33,025.
It is down -1.32% in the last 24 hours and down -45.37% over the past month.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$1.135
Open:
$1.11
24h Volume:
33,025
Relative Volume:
0.06
Market Cap:
$58.56M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-0.6257
EPS:
-1.79
Net Cash Flow:
$-64.50M
1W Performance:
-39.78%
1M Performance:
-45.37%
6M Performance:
-17.65%
1Y Performance:
-80.32%
1-Day Range:
$1.11
$1.131
1-Week Range:
$1.08
$1.97
52-Week Range:
$1.02
$6.225
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.116 | 64.41M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
413.76 | 105.80B | 11.70B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
647.49 | 67.70B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.14 | 57.41B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.62 | 51.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.71 | 39.86B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
Is TScan Therapeutics Inc. stock attractive for ETFsCPI Data & AI Driven Price Forecasts - fcp.pa.gov.br
Growth Value: Will TScan Therapeutics Inc. stock benefit from green energy trendsEarnings Recap Summary & Detailed Earnings Play Strategies - fcp.pa.gov.br
Should you wait for a breakout in TScan Therapeutics Inc.July 2025 Spike Watch & Daily Market Momentum Tracking - newser.com
Technical signs of recovery in TScan Therapeutics Inc.GDP Growth & Daily Entry Point Trade Alerts - newser.com
Trend analysis for TScan Therapeutics Inc. this week2025 Year in Review & Risk Controlled Swing Trade Alerts - newser.com
TScan Therapeutics (NASDAQ:TCRX) Price Target Cut to $6.00 by Analysts at Needham & Company LLC - Defense World
TScan Therapeutics (TCRX) Projected to Post Earnings on Tuesday - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Price Target Lowered to $6.00 at Needham & Company LLC - MarketBeat
The time has not yet come to remove your chips from the table: Tscan Therapeutics Inc (TCRX) - setenews.com
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - The Manila Times
Reversal indicators forming on TScan Therapeutics Inc. stockMarket Performance Report & Growth Focused Investment Plans - newser.com
Barclays Reaffirms Their Buy Rating on TScan Therapeutics (TCRX) - The Globe and Mail
Is TScan Therapeutics Inc. stock positioned well for digital economyWeekly Trend Recap & Free Weekly Watchlist of Top Performers - newser.com
Best data tools to analyze TScan Therapeutics Inc. stockWeekly Market Report & Expert Curated Trade Setup Alerts - newser.com
How TScan Therapeutics Inc. stock performs in high volatility marketsCPI Data & Accurate Entry and Exit Point Alerts - newser.com
TScan Therapeutics Shares Fall After BTIG Research Downgrade - MarketScreener
Biotech firm TScan slashes jobs, extends cash runway amid strategic realignment - The Business Journals
BTIG downgrades Tscan Therapeutics stock to Neutral on program delays By Investing.com - Investing.com Australia
BTIG downgrades Tscan Therapeutics stock to Neutral on program delays - Investing.com India
BTIG Research Downgrades TScan Therapeutics to Neutral From Buy - MarketScreener
Needham Maintains TScan Therapeutics (TCRX) Buy Recommendation - Nasdaq
TScan Therapeutics (TCRX) Analyst Update: Needham Lowers Price T - GuruFocus
Applying chart zones and confluence areas to TScan Therapeutics Inc.Earnings Growth Report & Precise Swing Trade Entry Alerts - newser.com
How TScan Therapeutics Inc. stock reacts to global recession fears2025 Winners & Losers & Fast Entry High Yield Tips - newser.com
TScan to focus on heme program, cuts workforce by 30% amid FDA progress - Investing.com Nigeria
Is TScan Therapeutics Inc. stock gaining market shareVolume Spike & Growth Oriented Trade Recommendations - fcp.pa.gov.br
Tscan Therapeutics stock plunges after pausing solid tumor trial enrollment By Investing.com - Investing.com Australia
Tscan Therapeutics stock plunges after pausing solid tumor trial enrollment - Investing.com
How TScan Therapeutics Inc. stock performs in rate cut cyclesRecession Risk & Low Risk Entry Point Tips - newser.com
What technical models suggest about TScan Therapeutics Inc.’s comebackExit Point & Weekly Watchlist of Top Performers - newser.com
Using data filters to optimize entry into TScan Therapeutics Inc.Weekly Risk Report & High Yield Equity Trading Tips - newser.com
TScan Therapeutics Shifts Focus to Hematologic Malignancies - MSN
TScan Therapeutics Announces Positive Phase I Meeting with FDA, Strategic Workforce Reduction, and Focus on Hematologic Malignancies - Quiver Quantitative
TScan Therapeutics Announces 30% Workforce Reduction, Cash Runway Extension - TradingView
TScan Therapeutics expects $2.3 million one-time charge for severance during 3 months ended Dec 31 - MarketScreener
TScan Therapeutics Expects $2.3 Million One-Time Charge For Severance During 3 Months Ended Dec 31 - TradingView
TScan Therapeutics Reaches Agreement with FDA on Pivotal - GlobeNewswire
Is TScan Therapeutics Inc. building a consolidation base2025 Year in Review & Stock Timing and Entry Methods - newser.com
Can swing trading help recover from TScan Therapeutics Inc. lossesTrade Risk Summary & Comprehensive Market Scan Insights - newser.com
Can TScan Therapeutics Inc. stock maintain growth trajectoryEarnings Growth Report & Community Trade Idea Sharing - newser.com
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tscan Therapeutics Inc Stock (TCRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
May 20 '25 |
Buy |
1.20 |
1,200,000 |
1,440,000 |
7,946,141 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 13 '24 |
Buy |
2.90 |
100,000 |
290,140 |
5,357,347 |
| Lynx1 Capital Management LP | 10% Owner |
Dec 12 '24 |
Buy |
3.01 |
31,800 |
95,629 |
5,257,347 |
| Lynx1 Capital Management LP | 10% Owner |
Nov 15 '24 |
Buy |
4.34 |
947 |
4,114 |
5,225,547 |
0.99%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):